호일바이오메드

비상장계속사업자

HOIL BioMed INC.

김기옥

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

호일바이오메드

Business Reg. No. 2098113983 · CEO 김기옥

I.Investment Overview

Target호일바이오메드 (2098113983)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명호일바이오메드
영문명HOIL BioMed INC.
대표자김기옥
사업자등록번호2098113983
법인등록번호1101110668959
설립일1990.01.17
종업원수19명

V.Workforce

19

Current headcount · 2026.06 as of

VI.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW2722021359.22022292.32023176.62024161.82025
영업이익100M KRW14.1202120.1202210.320230.92024-1.72025
순이익100M KRW16202119.52022920231.120240.62025
Item20252024202320222021
자산총계137.9억원164.1억원211억원247.7억원296.7억원
부채총계7.9억원21.3억원34.4억원65.9억원63.2억원
자본총계130억원142.8억원176.6억원181.8억원233.5억원
매출액161.8억원176.6억원292.3억원359.2억원272억원
영업이익-1.7억원8,892만원10.3억원20.1억원14.1억원
순이익5,694만원1.1억원9억원19.5억원16억원

VII.Financial Ratios

FY2025 basis

-1.03%

영업이익률

0.35%

순이익률

0.41%

ROA

0.44%

ROE

6.12%

부채비율

94.24%

자기자본비율

VIII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

호일바이오메드 투심보고서 | Alpha Lenz